JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

The carcinoid syndrome: palliation by hepatic artery embolization.

A group of 25 patients with malignant carcinoid syndrome underwent hepatic artery embolizations to palliate the symptoms of this syndrome. Twenty-three patients could be evaluated: 20 (87%) of them responded to embolization with a median response duration of 11+ months, one (4%) did not respond, and two (9%) died of complications from the embolization. The symptomatic responses correlated with two variables: (1) a decrease in the extent of the hepatic metastases in 17 of the 18 patients who had follow-up hepatic imaging, and (2) a decrease in the urine 5-hydroxyindoleacetic acid values to a mean of 41% of pretreatment levels in the 18 patients for whom this test was available. Hepatic artery embolization provides the most effective treatment for the carcinoid syndrome and the hepatic metastases. Periodic embolizations will maintain clinical remissions for prolonged periods of time.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app